Disclosure of payments to physicians by pharmaceutical companies is currently mandated by numerous HHS OIG corporate integrity agreements. As of January 1, 2012, the Physician Payments Sunshine Act requires that all drug and device companies begin recording payments to physicians in order to begin reporting these payments in March 2013. Drug and device companies are anxiously awaiting draft regulations from the Centers for Medicare and Medicaid Services about how to implement the requirements of the new law. Meanwhile, the mainstream media is already featuring stories about drug company payments to doctors based on the public disclosures made by several large pharmaceutical companies.
The Fourth Annual Summit on Disclosure Transparency and Aggregate Spend for Drug, Device and Biotech Companies will offer pharmaceutical and medical device professionals with the first opportunity to assess the practical experience of their peers after the January 1, 2012 "go live" date. The Summit will also provide expert advice on the myriad operational questions that companies are now confronting. In-house experts will share their experience on a wide array of emerging best practices ranging from project management to building scalability and sustainability. Panels of outside experts and third parties who have been in the vanguard of building and implementing aggregate spend solutions will also weigh in on what is working and not working. The Summit will also feature senior regulators from state and federal agencies to update attendees on the government's latest thinking in this area.
WHO SHOULD ATTEND
- Pharmaceutical and Health Care Executives
- Medical Device Executives
- Compliance Officers
- Ethics Officers
- General Counsel and Legal Executives
- Finance Executives
- Information Management and Information Technology Executives
- Medical Affairs Directors
- Food and Drug Law Attorneys
- Privacy Officers
- Pharmaceutical Consultants
- Health Care Regulators and Policy Makers
- Health Services Researchers and Academics